Direkt zum Inhalt
Merck
  • Rapid detection of a point mutation in the parC gene associated with decreased susceptibility to fluoroquinolones in Mycoplasma bovis.

Rapid detection of a point mutation in the parC gene associated with decreased susceptibility to fluoroquinolones in Mycoplasma bovis.

Antimicrobial agents and chemotherapy (2009-09-02)
I Lysnyansky, I Mikula, I Gerchman, S Levisohn
ZUSAMMENFASSUNG

Comparison of the quinolone resistance-determining regions (QRDRs) in 42 Mycoplasma bovis clinical isolates revealed amino acid substitutions at both GyrA (position 83) and ParC (position 84) in 10/11 enrofloxacin-resistant strains. The mutation present in the parC QRDR was discriminative for enrofloxacin resistance by parC PCR-restriction fragment length polymorphism. Comparison of molecular profiles by insertion sequence typing suggests that the currently prevalent enrofloxacin-resistant M. bovis strain evolved by selection under field conditions from one of the susceptible strains.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Enrofloxacin, ≥99.0%
Supelco
Enrofloxacin, VETRANAL®, analytical standard